This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wong, P. C. Articles by Timmermans, P. B. Search for Related Content PubMed PubMed Citation Articles by Wong, P. C. Articles by Timmermans, P. B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Hazardous Substances DB CAPTOPRIL FUROSEMIDE LOSARTAN POTASSIUM

Hypertension, Vol 15, 459-468, Copyright © 1990 by American Heart Association

ARTICLES

Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X

PC Wong, WA Price Jr, AT Chiu, JV Duncia, DJ Carini, RR Wexler, AL Johnson and PB Timmermans
Medical Products Department, E.I. du Pont de Nemours & Company, Wilmington, DE 19880-0400.

In conscious 18-21-week-old spontaneously hypertensive rats, DuP 753, a nonpeptide angiotensin II receptor antagonist, given orally at 3 and 10 mg/kg or intravenously at 3, 10, and 30 mg/kg, reduced blood pressure dose dependently. It did not alter heart rate at these doses. At 10 mg/kg i.v., DuP 753 decreased blood pressure significantly for at least 24 hours, suggesting a long duration of the antihypertensive effect. Unlike saralasin, DuP 753 did not cause a transient increase in blood pressure. The acute antihypertensive efficacy of DuP 753 was greater than that of captopril. Our data indicate that, for captopril to reduce blood pressure to a similar extent as that of DuP 753, it would need to be supplemented by a diuretic. DuP 753 did not have an acute diuretic effect. Bilateral nephrectomy, but not inhibition of prostaglandin synthesis, abolished the antihypertensive effect of DuP 753, suggesting that the antihypertensive effect of DuP 753 is dependent on an active renin-angiotensin system. Furthermore, DuP 753 inhibited the pressor response to angiotensin II but not the responses to norepinephrine, vasopressin, and Bay K 8644 (a calcium agonist). As neither DuP 753 nor captopril decreased blood pressure acutely in Wistar-Kyoto normotensive rats, our results suggest that the renin-angiotensin system plays a significant role in the control of blood pressure in spontaneously hypertensive rats.

This article has been cited by other articles:

				S. M. Gardiner, J. E. March, P. A. Kemp, S. A. Ballard, and T. Bennett Regional Hemodynamic Effects of Neutral Endopeptidase Inhibition and Angiotensin (AT1) Receptor Antagonism Alone or in Combination in Conscious Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 340 - 348. [Abstract] [Full Text] [PDF]

				R. J. Bolterman, M. C. Manriquez, M. C. O. Ruiz, L. A. Juncos, and J. C. Romero Effects of Captopril on the Renin Angiotensin System, Oxidative Stress, and Endothelin in Normal and Hypertensive Rats Hypertension, October 1, 2005; 46(4): 943 - 947. [Abstract] [Full Text] [PDF]

				J. F. Reckelhoff and J. C. Romero Role of oxidative stress in angiotensin-induced hypertension Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R893 - R912. [Abstract] [Full Text] [PDF]

				W. Wienen and H.-J. Schierok Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats Journal of Renin-Angiotensin-Aldosterone System, June 1, 2001; 2(2): 123 - 128. [Abstract] [PDF]

				P. Li, M. Fukuhara, D. I. Diz, C. M. Ferrario, and K. B. Brosnihan Novel Angiotensin II AT1 Receptor Antagonist Irbesartan Prevents Thromboxane A2-Induced Vasoconstriction in Canine Coronary Arteries and Human Platelet Aggregation J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 238 - 246. [Abstract] [Full Text]

				D. H. Wang and J. Li Antihypertensive Mechanisms Underlying a Novel Salt-Sensitive Hypertensive Model Induced by Sensory Denervation Hypertension, January 1, 1999; 33(1): 499 - 503. [Abstract] [Full Text] [PDF]

				P. Gohlke, C. Pees, and T. Unger AT2 Receptor Stimulation Increases Aortic Cyclic GMP in SHRSP by a Kinin-Dependent Mechanism Hypertension, January 1, 1998; 31(1): 349 - 355. [Abstract] [Full Text] [PDF]

				J. Magga, O. Vuolteenaho, M. Marttila, and H. Ruskoaho Endothelin-1 Is Involved in Stretch-Induced Early Activation of B-Type Natriuretic Peptide Gene Expression in Atrial but Not in Ventricular Myocytes : Acute Effects of Mixed ETA/ETB and AT1 Receptor Antagonists In Vivo and In Vitro Circulation, November 4, 1997; 96(9): 3053 - 3062. [Abstract] [Full Text]

				J. Menard, D. J. Campbell, M. Azizi, and M.-F. Gonzales Synergistic Effects of ACE Inhibition and Ang II Antagonism on Blood Pressure, Cardiac Weight, and Renin in Spontaneously Hypertensive Rats Circulation, November 4, 1997; 96(9): 3072 - 3078. [Abstract] [Full Text]

				P. Li, C. M. Ferrario, and K. B. Brosnihan J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1065 - 1070. [Abstract] [Full Text]

				S. K. Gandhi, D. H. Ryder, and N. J. Brown Losartan Blocks Aldosterone and Renal Vascular Responses to Angiotensin II in Humans Hypertension, December 1, 1996; 28(6): 961 - 966. [Abstract] [Full Text]

				M. T. Velasquez Angiotensin II Receptor Blockers: A New Class of Antihypertensive Drugs Arch Fam Med, June 1, 1996; 5(6): 351 - 356. [Abstract] [PDF]

				J. H. Bauer and G. P. Reams The Angiotensin II Type 1 Receptor Antagonists: A New Class of Antihypertensive Drugs Arch Intern Med, July 10, 1995; 155(13): 1361 - 1368. [Abstract] [PDF]

				D. H. Sigmon and W. H. Beierwaltes Endothelium-Derived Constricting Factor in Renovascular Hypertension Hypertension, April 1, 1995; 25(4): 803 - 808. [Abstract] [Full Text]

				A. H. van den Meiracker, P. J.J. Admiraal, J. A. Janssen, J.-M. Kroodsma, W. A.M. de Ronde, F. Boomsma, J. Sissmann, P.J. Blankestijn, P. G.M. Mulder, A. J. Man in `t Veld, et al. Hemodynamic and Biochemical Effects of the AT1 Receptor Antagonist Irbesartan in Hypertension Hypertension, January 1, 1995; 25(1): 22 - 29. [Abstract] [Full Text]